Daily Hong Kong Stock Market News Briefing (February 20, Thursday)

UBTECH ROBOTICS announced on the Hong Kong Stock Exchange that it will place 10,155,099 new H shares at a placement price of HKD 90.00 per H share.

IMAX China (01970.HK): The net profit for the full year 2024 is expected to be USD 22.2 million, compared to USD 27.5 million in the same period last year.

HUISHANG BANK (03698.HK): The net profit for the year 2024 is expected to be approximately CNY 15.9 billion, a year-on-year increase of about 6%.

Tianqi Lithium (09696.HK): The TLEA management has conducted an asset impairment test for its overseas lithium hydroxide project.

Cathay Pacific Airways (00293.HK): In January, passenger numbers reached 2.352 million, an increase of 37% year-on-year.

LeCang Logistics (02490.HK): The net profit for 2024 is expected to be between CNY 359 million and CNY 419 million, a year-on-year increase of 199% to 249%.

PCPD (00432.HK): The revenue for 2024 is expected to be HKD 9.01 billion, a year-on-year increase of 9.61%, with a net loss of HKD 230 million, narrowing by 50.64% year-on-year.

HAOHAI BIOTEC (06826.HK): The revenue for 2024 is expected to be CNY 2.698 billion, a year-on-year increase of 1.64%; the net profit attributable to the parent company is expected to be CNY 420 million, a year-on-year increase of 0.97%.

Ascletis Pharma-B (01672.HK): The first two cohorts of the Phase Ib multi-dose escalation study of the small molecule oral GLP-1R agonist ASC30 in the United States have achieved positive interim results